Search All Applications in Cannabis: Compositions
Application US20200061138
Published 2020-02-27
Genetically Modified Cannabis Sativa Plants And Modified Cannabinoid Compounds For Treatment Of Substance Addiction And Other Disorders
A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase. The overexpression of THCA synthase and CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to tetrahydrocannabinolic acid and cannabidiolic acid, as well as the cannabinoids (3aR)-2,4,4-trimethyl-7-pentyl-3,3a,4,9b-tetrahydrocyclopenta[c]chromen-9-ol and 2-((1R,5R)-3-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-5-pentylbenzene-1,3-diol. Pharmaceutical compositions comprising the modified cannabinoids produced by the transgenic Cannabis sativa plant or prepared synthetically are used to treat various diseases and conditions.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1. A method of increasing a cannabinoid level in a Cannabis sativa plant, comprising:
genetically modifying the Cannabis sativa plant with a genetic modification, wherein the genetic modification induces the Cannabis sativa plant to overexpress a gene controlling the expression of a cannabidiolic acid (CBDA) synthase, wherein the CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to cannabidiolic acid, and wherein the cannabidiolic acid is converted into an increased cannabinoid level in the plant, wherein the cannabinoid is a compound having the structure:
- 10. A compound having the structure: or a pharmaceutically acceptable salt thereof.
